Last reviewed · How we verify
EPORON
EPORON is an erythropoietin (EPO) receptor agonist that stimulates red blood cell production to treat anemia.
EPORON is an erythropoietin (EPO) receptor agonist that stimulates red blood cell production to treat anemia. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.
At a glance
| Generic name | EPORON |
|---|---|
| Also known as | Erythropoietin Alpha, EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU) |
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Erythropoietin receptor agonist |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
EPORON activates erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting proliferation and differentiation into mature red blood cells. This mechanism increases hemoglobin and hematocrit levels, effectively treating anemia associated with chronic kidney disease, cancer chemotherapy, or other conditions causing reduced red blood cell production.
Approved indications
- Anemia associated with chronic kidney disease
- Chemotherapy-induced anemia
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
Key clinical trials
- Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (PHASE2)
- To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) (PHASE3)
- To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |